MAUNA KEA TECHNOLOGIES (EPA:MKEA) Mauna Kea Technologies: surgeons successfully use Cellvizio for immediate confirmation of cancer in brain and spinal tumors
Transparency directive : regulatory news
25/08/2015 18:00
Click here to download pdf version
PRESS RELEASE
SURGEONS SUCCESSFULLY USE CELLVIZIO FOR IMMEDIATE CONFIRMATION OF CANCER IN
BRAIN AND SPINAL TUMORS
Research breakthrough shows technology could help neurosurgeons target brain
tumors with greater precision while protecting healthy tissue
Study was performed at Cologne Medical Center in collaboration with Siemens
Corporate Technology and Mauna Kea Technologies
PARIS, France - August 25, 2015 - Mauna Kea Technologies (Euronext: MKEA; ISIN:
FR0010609263, PEA- PME eligible), inventor of Cellvizio(r), a multidisciplinary
confocal laser endomicroscopy (CLE) platform, today announced that results of a
new study involving the use of CLE with Cellvizio were published in the peer
reviewed journal Neurosurgery*. Results showed that use of Cellvizio provides
real time histomorphological diagnosis of pathology with results similar to use
of traditional surgical biopsy. Diagnosis with conventional histology can take 5
to 10 days.
These results were initially presented at the Congress of Neurological Surgeons
2014 in Boston, MA, USA and were awarded with the National Brain Tumor Society
Mahaley Clinical Research Award.
Siemens Corporate Technology provided support for the Cellvizio device used in
this study during which fresh surgical biopsies of 150 intracranial and
intraspinal lesions were examined to test the signal intensity and adequate
contrast for Cellvizio imaging. A combination of ex vivo biopsies was compared
to standard histology. Cellvizio yielded consistently high-quality
histomorphology of brain and spinal tumors, allowing a 1000-fold magnification
of observed tissue structures during surgery, whereas commonly used microscopy
and standard endoscopy offer a 25-fold and 2-fold magnification respectively.
"Surgeons can face significant challenges in developing a precise assessment of
tumor margins in brain tissue. The ability to differentiate tissue in real time
with this level of magnification and precision is a very significant advantage,"
said Cleopatra Charalampaki, MD, PhD, department of neurosurgery at Hospital
Merheim, Cologne Medical Center, Cologne, Germany. "These important new data
provide strong validation of the mechanism of action of CLE with Cellvizio to
support faster and more effective perioperative delineation between healthy and
pathological tissue".
According to the research team led by Professor Charalampaki, potential benefits
of use of Cellvizio-assisted surgery in diagnosis of brain and spinal tumors
include immediate diagnosis to support faster post-operative disease management,
and more effective delineation between healthy and pathological tissues that can
lead to improvements in surgical resection and prognosis.
"This is yet another example of a high-quality investigator initiated study
bringing to light a novel use of Cellvizio with high clinical and market
potential. By providing surgeons with a tool to image brain tissue in real
time, Cellvizio has the potential to completely transform the diagnosis and
treatment of these tumors in the years ahead, leading to faster diagnosis, more
accurate assessments of tumor margins, and improved surgical resections", said
Sacha Loiseau, founder and CEO of Mauna Kea Technologies. "Importantly, these
findings in the central nervous system also support the potential use of
Cellvizio in the diagnosis and imaging of many other forms of cancer".
* Link to the article:
http://journals.lww.com/neurosurgery/Fulltext/2015/08001/
Confocal_Laser_Endomicroscopy_for_Real_time.32.aspx
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company focused on protecting
patient lives by enabling physicians and surgeons to make better decisions
thanks to direct visualization at the cellular level. The company's flagship
product, Cellvizio(r) has received clearance for a broad range of applications
in more than 40 countries including the United-States, Europe, Japan, China,
Canada, Brazil and Mexico.
For further information on Mauna Kea Technologies, visit www.maunakeatech.com
Mauna Kea Technologies
Eric Cohen
Vice President Finance
Tél. : +33 (0)1 70 08 09 70
investor-vpf@maunakeatech.com
France & Europe
NewCap - Investor Relations
Florent Alba / Pierre Laurent
Tél. : +33 (0)1 44 71 94 94
maunakea@newcap.fr
United States
Berry & Company Public Relations
Bill Berry
Tel: +1 212 253 8881
bberry@berrypr.com